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The host innate immune response provides a critical first line of defense against invading pathogens,
inducing an antiviral state to impede the spread of infection. While numerous studies have documented
antiviral responses within actively infected tissues, few have described the earliest innate response induced
systemically by infection. Here, utilizing Venezuelan equine encephalitis virus (VEE) replicon particles (VRP)
to limit infection to the initially infected cells in vivo, a rapid activation of the antiviral response was
demonstrated not only within the murine draining lymph node, where replication was confined, but also within
distal tissues. In the liver and brain, expression of interferon-stimulated genes was detected by 1 to 3 h
following VRP footpad inoculation, reaching peak expression of >100-fold over that in mock-infected animals.
Moreover, mice receiving a VRP footpad inoculation 6, 12, or 24 h prior to an otherwise lethal VEE footpad
challenge were completely protected from death, including a drastic reduction in challenge virus titers. VRP
pretreatment also provided protection from intranasal VEE challenge and extended the average survival time
following intracranial challenge. Signaling through the interferon receptor was necessary for antiviral gene
induction and protection from VEE challenge. However, VRP pretreatment failed to protect mice from a
heterologous, lethal challenge with vesicular stomatitis virus, yet conferred protection following challenge with
influenza virus. Collectively, these results document a rapid modulation of the host innate response within
hours of infection, capable of rapidly alerting the entire animal to pathogen invasion and leading to protection
from viral disease.
Venezuelan equine encephalitis virus (VEE) is an arthro-
pod-borne, single-stranded, message-sense RNA virus belong-
ing to the Alphavirus genus and Togaviridae family. Associated
with periodic epidemics and equine epizootics in the Western
Hemisphere, VEE also serves as a leading model for the study
of alphavirus pathogenesis in vivo. In the murine model, which
closely mimics infection of horses in nature, VEE causes a
two-phase disease: an initial, acute lymphotropic phase char-
acterized by a high serum viremia, followed by invasion of the
central nervous system during a neurotropic phase that leads to
fatal encephalitis (22, 27). Using the infectious molecular clone
of VEE and an extensive panel of mutants blocked at various
stages of infection, the course of infection and disease in the
mouse model has been well characterized (3, 14, 15, 17, 27).
Studies examining the molecular aspects of VEE pathogen-
esis have underscored the critical role of virus genetics and the
subsequent host response in dictating the course and outcome
of infection (6, 12, 23, 27, 35, 60, 64, 73). However, many
details of the earliest host-pathogen interactions during VEE
infection remain largely unknown. A tool paramount to study-
ing early events in infection are VEE replicon particles (VRP).
VRP are propagation-defective particles that undergo only one
round of infection, as the structural genes which normally drive
the assembly of progeny virions are deleted from the replicon
genome (51). Infection of cells by VRP results in amplification
of replicon viral RNA, but there is no packaging of new prog-
eny and thus no further spread to other cells. As such, VRP
infection is limited to the first round of targeted cells, allowing
examination of the earliest interactions between virus and host.
VRP infection of mice facilitated the identification of the
draining lymph node (DLN) as the initial site of VEE viral
amplification in vivo (44). Following footpad inoculation of
mice with VRP, resident dendritic cells in the skin serve as the
cellular target for infection. These infected dendritic cells then
rapidly migrate from the site of inoculation in the skin to the
local DLN (44). In the case of VRP infection, while no new
viral progeny are packaged or released, the replicon genome
continues to be replicated within these initially infected skin
dendritic cells that have migrated and reside in the DLN.
However, during infection with VEE virus, new viral progeny
are eventually released into the DLN environment and infec-
tion spreads to adjacent cells.
Based on these observations, we hypothesize that the earli-
est host-pathogen interactions within the DLN set the stage for
the specific course of events that define VEE-induced patho-
genesis. The innate immune response, including interferon
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(IFN) signaling, has been extensively documented as a critical
component of controlling viral infection and spread (45, 47, 62,
66). In fact, utilizing a VRP-based mRNP-tagging system in
vivo, we recently reported the robust activation of the host
innate antiviral response directly within the infected cells of
the DLN, as well as in surrounding uninfected bystander cells,
at early times postinoculation (39). A consequence of this
early, robust innate immune response at the initial site of
replication is likely a contemporaneous induction of an antivi-
ral state in tissues distal to the primary infection.
We postulated that if early viral replication in the DLN
induces the production of soluble immune mediators, such as
IFN-/, then the induction of innate immune responses may
be rapidly transmitted downstream from this primary site to
distal tissues. Utilizing VRP to limit viral spread, we examined
the host antiviral response within the DLN and tissues remote
from the site of replication at early times following infection.
In the liver and brain, the robust expression of a panel of
IFN-stimulated genes, a hallmark of the antiviral state, was
detected by 1 to 3 h following VRP footpad inoculation and
peaked at expression levels 100-fold over mock animals.
These results suggest that the early innate response to VRP
infection is capable of rapidly inducing a systemically active
antiviral state within the entire infected animal. Moreover, we
found that mice pretreated by footpad inoculation with VRP
for 6, 12, or 24 h were protected from an otherwise lethal VEE
footpad or intranasal challenge, and the average survival time
of mice challenged intracranially with VEE was significantly
extended.
Protection from VEE infection has typically been associated
with the presence of neutralizing antibody (11, 24, 29, 49, 55).
However, nonspecific protection against VEE has been sug-
gested, including the involvement of the innate immune re-
sponse (10, 26, 28, 33, 61, 73). In one instance, mice “vacci-
nated” with an attenuated clone of VEE were protected
against lethal VEE challenge administered just 24 h after vac-
cination (26). In separate studies, the complete attenuation of
a VEE mutant harboring a single noncoding nucleotide change
was attributed to a heightened sensitivity of the virus to the
host antiviral state (73). Additionally, mice with severe com-
bined immunodeficiency survive longer than immunocompe-
tent mice (9 days as opposed to 6 days) following infection with
virulent VEE (12). These findings firmly indicate that the non-
specific host response to VEE is a critical component of con-
trolling the earliest stages of infection.
While IFN and the IFN-induced antiviral state are undoubt-
edly key mediators of the initial response to VRP infection in
vivo, they may not solely be responsible for a rapidly induced
protective state. In the challenge model presented here, VRP
pretreatment was unable to protect mice from death following
heterologous challenge with another IFN-sensitive virus, vesic-
ular stomatitis virus (VSV). However, VRP pretreatment suc-
cessfully protected mice from lethal challenge with influenza
virus. Collectively, our results raise at least three important
implications. First, the innate host response is rapidly mobi-
lized following infection with VRP/VEE, at areas both proxi-
mal and distal to the site of active replication. Second, there
exist components of the innate immune response to VEE that
remain uncharacterized. Third, viruses are specifically and dif-
ferentially sensitive to unique innate immune response pro-
files. These data provide new insight into the rapid mobiliza-
tion of the host response to viral infection and present an
effective pretreatment/challenge model to further investigate
specific components of the innate response critical to protec-
tion against infectious pathogens.
MATERIALS AND METHODS
Virus and replicon particles. The construction of the full-length VEE cDNA
clone pV3000, derived from the Trinidad donkey isolate of VEE, has been
described previously (15, 17, 27). Virus stocks of wild-type virulent VEE (V3000)
were produced by electroporating infectious RNA into BHK-21 cells (12, 27).
Virus particles were harvested from the supernatant at 24 h postinfection, when
significant cytopathic effect was evident, and were clarified by centrifugation, and
virus stocks were further concentrated by being pelleted through 20% (wt/vol)
sucrose in low-endotoxin phosphate-buffered saline (PBS). Virus titers were
determined by standard plaque assay on BHK-21 cells, and stocks were stored in
single-use aliquots at 70°C.
The construction and packaging of VRP using a split helper system have been
described previously (51). Replicon plasmid constructs that do not encode any
functional transgene sequence downstream of the 26S promoter were utilized
throughout this study. The resulting particles, termed “null VRP,” contain the
VEE nonstructural genes, 14 nucleotides (nt) of VEE sequence downstream of
the 26S mRNA transcription start site, and the 43-nt multiple cloning site (69).
The null VRP genome also includes the authentic viral 5 and 3 untranslated
regions. All replicon particles used in this study were packaged in the wild-type
(V3000) VEE envelope, with the absence of propagating recombinant virus
confirmed by blind passage in BHK-21 cells, as described previously (51).
BHK-21 titers were determined by immunocytochemistry using mouse sera con-
taining antibody to the VEE nonstructural proteins.
For VSV challenge experiments, the Orsay strain (Indiana-1 serotype) of VSV
was the generous gift of Douglas Lyles and John Connor (Wake Forest Univer-
sity, Winston-Salem, NC). Strain A/PR/8/34 was used for influenza virus chal-
lenge experiments.
Cells. BHK-21 cells (ATCC CCL-10) and murine L929 fibroblasts (ATCC
CCL-1) were maintained in alpha-minimum essential medium (Gibco) supple-
mented with 10% donor calf serum, 10% tryptose phosphate broth, 0.29 mg of
L-glutamine/ml, 100 U of penicillin/ml, and 0.05 mg of streptomycin/ml (37°C,
5% CO2).
Mice. Specific-pathogen-free BALB/c mice were obtained commercially
(Charles River Laboratories). Unless otherwise noted, 10- to 12-week-old female
BALB/c mice were utilized. Breeding pairs of 129Sv/Ev mice deficient for the
IFN-/ receptor (IFN-R/ mice) were kindly provided by Barbara Sherry
(North Carolina State University, Raleigh). Mice were bred under specific-
pathogen-free conditions in the Department of Laboratory Animal Medicine
breeding colony facilities at the University of North Carolina, Chapel Hill (UNC-
CH). Age-matched wild-type 129Sv/Ev (129S6/SvEvTac) mice were obtained
commercially from Taconic (Germantown, NY). Animal housing and care were
in accordance with all UNC-CH Institutional Animal Care and Use Committee
(IACUC) guidelines. All mouse studies were performed in an environmentally
controlled room in a biosafety level 3 facility, allowing mice to acclimate for 3 to
5 days in the facility before experimental manipulation.
Mice pretreated with VRP were inoculated in the right rear footpad (RRFP)
with 2  106 infectious units (IU) of null VRP (unless otherwise stated) in 10 l
of low-endotoxin PBS diluent containing 1% donor calf serum. Mock-pretreated
animals received diluent alone. When footpad was the route of challenge, mice
received 10 PFU of wild-type virulent VEE (V3000) inoculated in the opposing
left rear footpad (LRFP) (10-l total volume). Mice challenged intranasally with
VEE received a dose of 103 PFU of wild-type VEE (V3000) in a 10-l volume,
with 5 l administered into each nare. Mice challenged intracranially were
anesthetized with isoflurane and inoculated with 103 PFU of wild-type virulent
VEE in 10 l diluent.
Mice challenged intranasally with VSV received a dose of 2  106 PFU of VSV
diluted in 20 l RPMI medium (Gibco), with 10 l administered into each nare.
Male BALB/c mice (5 to 7 weeks of age) were utilized for VSV challenge
experiments to adhere to established VSV intranasal challenge protocols and
avoid the reported natural resistance to lethal VSV infection in female mice (4,
20, 31, 32, 53). Mice challenged intranasally with influenza virus received a dose
of 12 PFU/mouse, delivering 25 l per nostril.
For morbidity and mortality studies, mice were monitored for clinical signs of
disease and weighed every 24 h for 14 to 18 days. Morbidity was defined as
greater than 10% weight loss and/or signs of clinical disease for 2 or more
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consecutive days. Clinical signs of disease included ruffled fur, hunching, ataxia,
paresis (dragging of hind limb), paralysis (complete loss of hind limb function),
and/or a moribund state. In the interest of animal welfare and in accordance with
UNC-CH IACUC guidelines, mice experiencing a loss in weight of more than
20% of starting weight while showing clinical signs of disease were euthanized.
To determine viral titers in the serum and brain, mice were euthanized by
anesthesia overdose, followed by cardiac puncture and exsanguination to collect
blood samples. Serum was separated in Microtainer tubes, aliquoted, and stored
at 70°C. Each animal was perfused with 1 PBS, and the brain was removed
by dissection, weighed, and stored at 80°C in a 20% (wt/vol) suspension of 1
PBS containing 1% donor calf serum, 110 mM Ca2, and 50 mM Mg2. After
one freeze-thaw cycle, the samples were homogenized and clarified by centrifu-
gation, and viral titers were assessed by standard BHK-21 plaque assay.
RNA isolation and cDNA synthesis. At the indicated times postinfection, mice
were euthanized and perfused with PBS. The draining popliteal lymph node,
liver, and brain were dissected and stored at 80°C in RNAlater (RNA stabili-
zation reagent; Ambion). According to the manufacturer’s protocol, tissue ho-
mogenates were prepared using a plastic pestle and handheld motor, as well as
passage through an 18-gauge needle. Total cellular RNA was isolated using the
RNeasy Protect kit (Qiagen).
A one-tube DNase treatment and reverse transcription protocol was used to
generate cDNA, using the SuperScript III reverse transcriptase first-strand
cDNA kit (Invitrogen). Total RNA (0.75 to 1.0 g in 10 l) was combined with
1 l 10 mM deoxynucleoside triphosphate (dNTP) mix (Amersham Biosciences),
4 l 5 SuperScript III reverse transcriptase buffer, 1 l 0.1 mM dithiothreitol,
1 l 40 U/l RNaseOUT (Invitrogen), and 1 l RQ1 RNase-free DNase (Pro-
mega). The samples were DNase treated at 37°C for 30 min, followed by the
addition of RQ1 stop solution (Promega) and heat inactivation of the samples.
Following the addition of random hexamer primers (150 ng; Invitrogen), reverse
transcription of the samples was continued in the same tube, according to the
SuperScript III protocol (Invitrogen).
Real-time PCR and analysis. Real-time PCR was performed to determine the
relative abundance of specific cellular mRNAs in tissues isolated from mock- and
VRP-infected animals (3 mice per group). TaqMan gene expression primer
probe sets (Applied Biosystems) for various target host messages were used, with
each reaction performed in a 25-l total volume, including 5 l cDNA. For all
samples, an equivalent amount of RNA was reverse transcribed and an internal
reference control of 18S rRNA was included. The default amplification profile
was performed in the ABI Prism 7000 real-time PCR system. Using 7000 se-
quence detection software (v1.2.3, Applied Biosystems), the results were con-
verted into cycle threshold (CT) values corresponding to the cycle number at
which the fluorescence of the PCR product reached significant levels above the
background level. Results are presented as gene expression (fold) in the infected
samples over that in the mock samples, analyzed using the well-established
2		CT method (ABI Prism 7000 sequence detection system user bulletin; Ap-
plied Biosystems).
IFN bioassay. The levels of type I IFN present in the serum of infected mice
were measured by a standard biological assay on L929 cells, as described previ-
ously (63, 73). Briefly, serum samples were diluted 1:10 in medium and acidified
to a pH of 2.0 for 24 h. Following neutralization to pH 7.4, the samples were
titrated by twofold dilutions and added to confluent monolayers of L929 murine
fibroblasts. Twenty-four hours after the addition of the serum, IFN-sensitive
encephalomyocarditis virus (2  105 PFU) was added to each well and incubated
at 37°C. At 18 to 24 h postinfection, 3-[4,5-dimethylthylthiazol-2yl]-2,5-diphe-
nyltetrazolium bromide (MTT; Sigma), an indicator of viable cells, was added to
each well. Absorbance was read on a microplate reader at 570 nm. Each plate
contained twofold dilutions of an IFN standard (Chemicon or R&D Systems),
ranging from 500 to 0.49 IU/ml. The concentration of type I IFN in each serum
sample was based on the standard curves generated with the IFN standard.
End-point titers were measured as the dilution at which an optical density
reading of 0.5 was reached, corresponding to 
50% protection of the cell
monolayer from encephalomyocarditis virus-induced cell death.
RESULTS
VRP infection rapidly induces a robust antiviral state at the
initial site of replication in vivo, as well as in remote down-
stream tissues. Several studies have highlighted the impor-
tance of the DLN during VEE infection (26, 27, 36, 39, 44, 68,
69, 73). Following footpad inoculation, Langerhans cells at the
site of inoculation are the initial cells infected, rapidly migrat-
ing to the lymph node draining the injection site. As such, it is
the DLN that serves as the earliest site for viral replication, not
the tissue surrounding the inoculation site (40, 44). Conse-
quently, the earliest host response to VEE infection is estab-
lished within the DLN, as demonstrated by the robust induc-
tion of the host antiviral gene response within the infected cells
of the DLN (26, 39). Accordingly, it has been hypothesized
that early events within the DLN set the stage for a specific
pattern of virus replication and subsequent host response.
To determine whether the antiviral state established early in
the DLN leads to a systemic response throughout the animal,
mice were inoculated in the RRFP with 2  106 IU of null
VRP. The VRP system effectively isolates the active infection
to the DLN, allowing us to separately examine the early impact
of infection at the site of primary replication and within distal
uninfected tissues. At 1, 3, 6, 12, and 24 h postinoculation,
serum was collected and each animal was perfused with PBS.
The proximal popliteal DLN, liver, and brain (including olfac-
tory bulbs) were dissected from each animal, and total RNA
was isolated. The expression levels of several host antiviral
genes (coding for IFN-, IP-10, p56, and Isgf3) were mea-
sured from each tissue sample by real-time PCR.
The results shown in Fig. 1 demonstrate a robust activation
of the innate immune response not only in the DLN (Fig. 1A),
but also in tissues remote from the site of active VRP RNA
replication (liver [Fig. 1B] and brain [Fig. 1C]). As early as 1 to
3 h following footpad inoculation, high levels of antiviral gene
induction were detected in the DLN, including IFN-, IP-10,
and p56 gene expression at levels of 100-fold over that in
mock-infected mice. This response peaked in the DLN at 6 to
12 h following footpad inoculation, with expression levels of
IP-10, p56, and IFN- climbing to 400- to 5,000-fold over that
in mock-infected animals. By 24 h, this response within the
DLN appeared to be waning. Interestingly, in studies monitor-
ing the migration of VEE-infected dendritic cells to the DLN,
the majority of dendritic cells reached the DLN from the
inoculation site within 30 min and appeared to plateau by 2 h
postinfection (44). Therefore, the VRP-induced antiviral re-
sponse observed in the DLN may correlate with the rapid
kinetics of dendritic cell migration, viral gene expression, and
eventual clearance of infected cells from the DLN.
The kinetics of the antiviral response in distal, uninfected
tissues were similar to those observed in the DLN: antiviral
gene responses were initially detected at 1 to 3 h postinfection
in the liver and brain, peaked at 6 to 12 h, and waned by 24 h.
Peak antiviral responses in the liver and brain reached levels of
10- to nearly 1,000-fold that in mock-pretreated animals, sug-
gesting that within mere hours the entire infected animal was
alerted to the presence of the invading pathogen and mounted
a systemic antiviral response reaching far beyond the site of
active replication. It is important to note that these distal
tissues were analyzed for the presence of VRP message and
subsequently found to be completely devoid of replicon RNA,
as measured by real-time PCR for VEE nsP1 message (data
not shown). Lymph nodes other than the popliteal DLN are
also consistently absent of viral antigen following VRP infec-
tion of mice, including the contralateral DLN (40, 44).
Although these remote organs did not encounter VRP, they
nevertheless were exposed to soluble, systemically circulating
immune mediators that were initially induced by active infec-
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tion in the DLN. In fact, high levels of biologically active IFN
were detected in the serum of VRP-pretreated mice (Fig. 2).
Serum IFN levels reached nearly 400,000 IU/ml by 6 h postin-
fection and correlated with a peak in antiviral gene response.
This intense IFN response following VRP infection is compa-
rable to that observed following infection with VEE virus, with
peak serum IFN levels following footpad inoculation with VEE
reaching up to 80,000 IU/ml (73). In addition, peak cytokine
gene induction (e.g., IFN-, interleukin-6, and interluekin-10)
in the DLN is reported to reach 10- to 100-fold over mock
expression by 24 h after footpad inoculation with VEE (26),
mirroring the kinetics of the VRP-induced innate response
observed here.
Short-duration VRP pretreatment protects mice from chal-
lenge with virulent VEE. The magnitude and rapidity of the
systemic antiviral state induced following VRP inoculation
prompted studies to investigate the protective capacity of this
response. To address whether VRP inoculation rapidly in-
duced a protective state, adult female BALB/c mice were in-
oculated with 2  106 IU of null VRP in the RRFP at 6, 12, or
24 h prior to lethal challenge with VEE (10 PFU) administered
into the opposing LRFP. Mice were weighed and observed
every 24 h for signs of clinical disease, comparing morbidity
and mortality to mice receiving a mock (diluent only) pretreat-
ment prior to virulent VEE challenge. The results (Fig. 3A)
demonstrate that pretreatment with 2  106 IU of VRP inoc-
ulated into the footpad, even just 6 h prior to a lethal VEE
challenge, can completely protect animals from death. All an-
imals receiving VRP pretreatment survived, including all pre-
treatment durations tested, thereby eradicating the 100% mor-
tality observed following VEE challenge. The incidence of
morbidity observed in VRP-treated animals was largely re-
duced as well, falling from 100% in mock-pretreated mice to a
range of 0 to 33% morbidity in mice receiving VRP, and
generally was limited to ruffling of the fur. Allowing even a
short 6-h window between VRP inoculation and VEE chal-
lenge was sufficient to effectively protect animals from death, a
testament to the effectiveness of the early antiviral response.
To further assess the protective nature of this VRP pretreat-
ment, more rigorous routes of VEE challenge were examined.
Inoculated peripherally, VEE induces an initial lymphotropic
phase characterized by a high serum viremia that seeds infec-
tion of the olfactory neuroepithelium, followed by invasion of
the central nervous system leading to fatal encephalitis (13,
27). By granting direct access to the olfactory neuroepithelium,
intranasal delivery of VEE bypasses the necessity of a high
serum viremia for establishment of the neurotropic disease
phase. When BALB/c mice were pretreated with a VRP foot-
pad inoculation (2  106 IU) for 12 or 24 h prior to virulent
intranasal VEE challenge (103 PFU), they were completely
protected from death (Fig. 3B). Pretreatment administered 6 h
prior to intranasal challenge protected 50% of mice from
death. This is in contrast to the 100% mortality resulting from
the same intranasal challenge of mock-pretreated animals.
Direct intracranial inoculation of VEE bypasses the require-
ment for viral neuroinvasion and serves as a means to directly
measure viral neurovirulence. In our studies, intracranial VEE
inoculation served as the most rigorous challenge route exam-
FIG. 1. Rapid, systemic activation of the host antiviral response
following VRP footpad inoculation. Adult BALB/c mice (3 mice per
group) were inoculated in the RRFP with 2  106 IU of null VRP or
were mock infected with diluent. At 1, 3, 6, 12, or 24 h following inocu-
lation, the mice were euthanized and then perfused with PBS, and tissues
were resected. Total cellular RNA was isolated, cDNA was synthesized,
and the expression of a panel of IFN-stimulated genes (coding for IFN-,
IP-10, p56, and Isgf3) was assessed by TaqMan real-time PCR in the
DLN (A), liver (B), and brain (C). The induction (fold) of each gene is
represented as expression in VRP-infected animals relative to expression
in mock-infected animals. Bars represent mean values  the standard
error of the mean.
FIG. 2. High levels of biologically active IFN are present in the
serum of VRP-infected mice. Adult BALB/c mice were inoculated in
the RRFP with 2  106 IU of null VRP. At 1, 3, 6, 12, or 24 h following
inoculation, the mice were euthanized, followed by cardiac puncture
and exsanguination to collect blood samples. Type I IFN present in the
serum was measured by standard IFN biological assay on L929 cells,
and the results are presented as IU per milliliter. Each bar represents
an individual animal, with the limit of detection (LOD) for the assay
indicated by a dotted line. The data in this and the previous figure
correspond to the same group of mice.
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ined. As demonstrated in Fig. 3C, VRP footpad pretreatment
failed to protect animals from death following intracranial
challenge with 103 PFU of VEE. Intracranial challenge with a
lower dose of VEE (10 PFU) also resulted in 100% mortality
of both mock- and VRP-pretreated animals (data not shown).
However, VRP-pretreated mice did exhibit a statistically sig-
nificant extension in average survival time compared to mock-
pretreated mice (Fig. 3C).
Taken together, the VEE challenge experiments demon-
strate that a remarkably-short-duration pretreatment with
VRP effectively protects animals from peripheral (footpad) or
mucosal (intranasal) challenge with virulent VEE. While the
same pretreatment regimen cannot protect animals against
direct intracranial administration of VEE, it does result in an
extension in survival time following challenge.
VRP pretreatment reduces viral load in the serum and brain
of mice challenged with VEE. To determine whether VRP
pretreatment functionally reduced or limited VEE replication
following challenge, virus titers in the serum and brain were
determined by standard plaque assay. At 6, 12, or 24 h follow-
ing the standard pretreatment of 2  106 IU null VRP in the
RRFP, mice were challenged in the LRFP with 10 PFU of
VEE. At 24 h postchallenge, serum was collected from the tail
vein, followed by PBS perfusion and resection of the brain
(including the olfactory bulbs) at 88 h postchallenge. Titers
from VRP-pretreated animals were compared to those from
mock-pretreated animals.
The results shown in Fig. 4 demonstrate that VRP pretreat-
ment dramatically reduces the viral load in serum and brain
following VEE footpad challenge. By 24 h postchallenge, se-
rum viremia in mock-pretreated animals had reached 6.5  105
PFU/ml, while the viral load in the serum of VRP-pretreated
animals was reduced by over 2 logs to 2.1  103 PFU/ml.
Furthermore, viral titers in the brain of mock-pretreated ani-
mals had reached nearly 7.5  106 PFU/g by 88 h postchal-
lenge, while in VRP-pretreated animals the amount of virus in
the brain was at or below the limit of detection. Therefore,
short-duration pretreatment with VRP effectively reduces
challenge virus load in both serum and the brain, thereby
controlling viral replication and spread following VEE chal-
lenge.
Protection from virulent VEE challenge is dependent on the
dose of VRP pretreatment. To elucidate factors fundamental to
the protection bestowed by VRP pretreatment, we first ad-
dressed the parameter of pretreatment dose. Adult BALB/c
FIG. 3. VRP pretreatment prior to peripheral and intranasal chal-
lenge with virulent VEE protects mice from death and extends the
average survival time of mice challenged intracranially. Adult BALB/c
mice (5 to 6 mice per group) were pretreated by inoculation in the
RRFP with 2  106 IU null VRP for 6, 12, or 24 h prior to peripheral
challenge with 10 PFU of VEE in the opposing LRFP (A), intranasal
challenge with 103 PFU of VEE (a dose necessary to achieve 100%
mortality in mock-pretreated animals) (B), or intracranial challenge
with 103 PFU of VEE (C). Mock-pretreated mice received diluent in
the RRFP 6 h prior to challenge. Animals were monitored daily for
morbidity and mortality. The ASTs following intracranial challenge
were as follows (mean  standard error): mock-pretreated mice, 2.7 
0 days; VRP-pretreated mice (6 h), 5.0  0 days (P  0.001); VRP-
pretreated mice (12 h), 5.0  0.3 days (P  0.001); and VRP-pre-
treated mice (24 h), 4.0  0.4 days (P  0.05). One-way analysis of
variance was used for statistical analysis performed on AST values
following intracranial challenge of VRP-pretreated animals compared
to mock-pretreated animals.
FIG. 4. VRP pretreatment dramatically reduces the viral load in
the serum and brain of animals challenged with VEE. Adult BALB/c
mice (3 mice per group) were pretreated by inoculation in the RRFP
with 2  106 null VRP for 6, 12, or 24 h prior to challenge with 10 PFU
of virulent VEE in the opposing LRFP. Mock-pretreated mice re-
ceived diluent 6 h prior to challenge. At 24 h postchallenge, serum was
collected by tail vein bleed. At 88 h postchallenge, mice were eutha-
nized and then perfused with PBS, and the brain (including the olfac-
tory bulbs) was resected. Challenge virus titers were determined by
standard plaque assay on BHK cells. Bars represent mean values  the
standard error of the mean. The assay limit of detection (LOD) is
indicated by the dotted line.
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mice were pretreated with decreasing doses of null VRP in the
RRFP and then challenged 6 h later in the opposing LRFP
with 10 PFU of virulent VEE. Consistent with our previous
results, mice that received the standard pretreatment dose of
2  106 IU of VRP were completely protected from death.
When the VRP pretreatment dose was reduced to 105 or 104
IU, protection against mortality was lost, suggesting a fairly
narrow dose threshold for the protective effect (Fig. 5A). How-
ever, it is possible that protection may have been observed if
pretreatment with a lower dose was extended beyond 6 h.
Challenge virus titers in the serum and brain were also
determined in mice receiving lower VRP pretreatment doses
(Fig. 5B). Titers following the standard VRP pretreatment of
2  106 IU remained below a threshold of 700 PFU/ml in
serum and 3.5  103 PFU/g in brain. However, consistent with
the lack of protection observed, challenge virus titers in the
serum and brain remained high in animals receiving less than
the standard pretreatment dose. Therefore, a dose-dependent
trend in the ability of pretreatment to control challenge virus
replication does exist.
Signaling through IFN-/R is necessary for induction of
the downstream antiviral gene response and protection from
virulent VEE challenge. We have demonstrated large amounts
of biologically active IFN circulating in the serum of VRP-
pretreated mice by 6 h postinoculation (Fig. 2). The kinetics of
this serum IFN response correlate with the induction of a
robust host antiviral gene response in pretreated animals (Fig.
1). We hypothesize that this rapidly induced innate antiviral
state mediates protection from death upon virulent virus chal-
lenge and used IFN-/R/ mice to investigate the role of
IFN signaling in our model.
Wild-type 129 or IFN-/R/ mice were inoculated with
2  106 IU of null VRP in the RRFP. At 6 h postinoculation,
the mice were euthanized and then perfused with PBS, and
liver and brain tissue were resected. Total RNA extracted from
these tissues was used to investigate whether signaling through
IFN-/R was required for the rapidly induced VRP antiviral
response in downstream tissues. The expression of the same
panel of four IFN-stimulated genes (coding for IFN-, IP-10,
p56, and Isgf3) was measured by real-time PCR and com-
pared to levels in mock-infected mice.
The results shown in Fig. 6A demonstrate a near complete
elimination of the downstream antiviral gene response at 6 h in
mice lacking IFN-/R. This is in stark contrast to the robust
responses measured in the same tissues isolated from wild-type
129 (IFN-/R/) mice. Therefore, the lack of IFN-/R
greatly impairs the early, systemic antiviral response that is
induced in the downstream tissues of wild-type animals.
Concordantly, protection against virulent VEE challenge
was also lost in IFN-/R/ mice following this short-dura-
tion VRP pretreatment (Fig. 6B). We have previously reported
equivalent levels of serum IFN circulating in wild-type 129 and
IFN-/R/ mice at early times after VRP footpad inocula-
tion, including at 6 h (73). As such, we utilized the VRP
pretreatment duration of 6 h in our studies comparing host
responses and challenge outcomes in wild-type 129 and IFN-
/R/ mice. It is important to note that by 12 h post-VRP
infection, serum IFN levels in IFN-/R/ mice have been
reported as being 
1 log lower than that in wild-type mice
(73). Thus, the possibility exists that the kinetics of systemic
antiviral responses may be shifted in IFN-/R/ mice.
Nonetheless, the sensitivity of alphaviruses to the host IFN
response has been well documented, in fact—most convinc-
ingly in studies utilizing mice deficient for the IFN-/R (28,
57, 61, 73). IFN-/R/ mice infected with VEE experience
a significantly shorter average survival time (AST) (30 h) than
wild-type mice (7.7 days), indicating that viral replication in
control mice is significantly restricted by IFN (73). This intrin-
sic sensitivity of VEE to IFN ultimately makes it difficult to
determine whether the lack of protection observed in our IFN-
/R/ experiment is truly due to a dampened or impaired
pretreatment response or is merely a function of the general
increased susceptibility of these mice to infection with VEE.
VRP pretreatment differentially protects mice from chal-
lenge with heterologous viruses. To address whether the pro-
tection imparted by short-duration VRP pretreatment extends
to other viruses, two heterologous challenge models were em-
ployed. VSV and influenza virus served as attractive heterol-
ogous challenge models as they have been extensively used in
studies of viral pathogenesis and the IFN response to infection.
The pathogenesis of VSV has been well described in mice (7,
46, 47, 53, 56, 58, 65). Mortality can be difficult to induce when
delivering VSV by subcutaneous inoculation, while the mortality
rate following intranasal inoculation of VSV averages 30 to 60%
when a high challenge dose (e.g., 106 PFU) is administered to
FIG. 5. VRP pretreatment dose is a critical parameter in mediating
protection against VEE challenge. Adult BALB/c mice (5 mice per
group) were pretreated with decreasing doses of null VRP (2  106 IU,
105 IU, or 104 IU) inoculated in the RRFP for 6 h prior to challenge
with 10 PFU of virulent VEE (LRFP). Mock-pretreated mice received
diluent 6 h prior to challenge. (A) Animals were monitored daily for
morbidity and mortality. (B) At 24 h postchallenge, serum was col-
lected by tail vein bleed. At 88 h postchallenge, mice were euthanized
and then perfused with PBS, and the brain (including the olfactory
bulbs) was resected. At each dose of VRP pretreatment, subsequent
challenge virus titers were determined by standard plaque assay on
BHK cells. Bars represent mean values  the standard error of the
mean. The assay limit of detection (LOD) is indicated by the dotted
line.
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adult mice (19, 20, 41). Intranasal inoculation of VSV delivers
virus to the neuroepithelium, where it replicates and spreads to
the olfactory bulb (31, 32, 53), similar to intranasal infection with
VEE. To address whether VRP pretreatment could protect mice
following a heterologous VSV challenge, 6- to 7-week-old male
BALB/c mice were inoculated in the RRFP with 2  106 IU of
null VRP and then intranasally challenged 24 h later with 2  106
PFU of VSV. The mice were monitored daily, and their weight
and clinical scores were recorded.
As demonstrated in Fig. 7A, pretreatment with VRP was not
FIG. 7. VRP pretreatment differentially protects mice from chal-
lenge with heterologous viruses. (A) VRP pretreatment does not
protect mice against heterologous challenge with VSV. Adult
BALB/c mice (7 or 8 mice per group) were pretreated by inocula-
tion in the RRFP with 2  106 IU of null VRP for 24 h prior to
intranasal challenge with 2  106 PFU of VSV. Mock-pretreated
mice received diluent 24 h prior to challenge. Animals were mon-
itored daily for morbidity and mortality. (B) Adult BALB/c mice (3
mice per group) were pretreated by inoculation in the RRFP with 2 
106 IU of null VRP for 6 or 24 h prior to intranasal challenge with 2 
106 PFU of VSV. Mock-pretreated mice received diluent 24 h prior to
challenge. At 88 h postchallenge, mice were euthanized and then
perfused with PBS, and the brain (including the olfactory bulbs) was
resected. Challenge virus titers were determined by standard plaque
assay on BHK cells. Bars represent mean values  the standard error
of the mean. (C) VRP pretreatment is capable of protecting mice from
death following lethal influenza virus challenge. Adult BALB/c mice (6
mice per group) were pretreated by inoculation in the RRFP with 2 
106 IU null VRP for 6, 12, or 24 h prior to intranasal challenge with 12
PFU of influenza virus. Mock-pretreated mice received diluent 6 h
prior to challenge. Animals were monitored daily for morbidity and
mortality.
FIG. 6. VRP-induced antiviral gene induction in the brain is dimin-
ished and VRP-mediated protection from challenge is abolished in
IFN-/R knockout mice. Adult wild-type 129 Sv/Ev or IFN-/R
knockout (IFN-/R/) mice were inoculated in the RRFP with 2 
106 IU of null VRP or were mock infected with diluent. (A) At 6 h
following inoculation, the mice were euthanized and then perfused
with PBS, and brain tissue was resected. Total cellular RNA was
isolated, and the expression of a panel of IFN-stimulated genes (cod-
ing for IFN-, IP-10, p56, and Isgf3) was assessed by TaqMan real-
time PCR. Black bars represent gene expression in wild-type 129 mice,
and striped bars represent gene expression in IFN-/R/ mice. The
induction (fold) of each gene is represented by expression in VRP-
infected animals relative to expression in mock-infected animals. Bars
represent mean values (3 animals per group)  the standard error of
the mean. (B) Adult wild-type (WT) 129 Sv/Ev (5 mice per group) or
IFN-/R/ mice (8 mice per group) were pretreated by inoculation
in the RRFP with 2  106 IU null VRP for 6, 12, or 24 h prior to
challenge with 10 PFU of virulent VEE in the opposing footpad.
Mock-pretreated mice received diluent 6 h prior to challenge. Animals
were monitored for morbidity and mortality every 6 h for the first 48 h
and every 24 h thereafter.
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sufficient to protect animals from death following intranasal
challenge with VSV. Furthermore, VRP pretreatment 6 or
24 h prior to VSV intranasal challenge did not prevent VSV
from reaching the brain nor did it limit the level of challenge
virus replication (Fig. 7B). A challenge dose of 2  106 PFU of
VSV was required to induce a modest level of mortality in
mock-pretreated animals (Fig. 7A), reflecting the relatively
high dose of VSV that is traditionally required to induce mor-
tality when delivered to adult mice intranasally (7, 20, 31, 32).
Nonetheless, our results suggest that the magnitude or kinetics
of the host response were either not ideal or not sufficient to
control viral replication and bestow protection from this VSV
challenge.
Experimental infection of mice with influenza virus has also
long provided a model for studying viral pathogenesis (18, 21,
72, 74), with replication occurring in the upper and lower
respiratory tract following intranasal inoculation. In contrast to
the VSV studies, VRP pretreatment was capable of protecting
mice challenged heterologously with influenza virus (Fig. 7C).
Mice receiving a VRP footpad inoculation 24 h prior to lethal
intranasal challenge with influenza virus (12 PFU) were pro-
tected from death (66.7% protection) (Fig. 7C). Interestingly,
this pretreatment was less effective if administered 12 h prior
to challenge (16.7% protection) and was ineffective when de-
livered 6 h prior to challenge. These results demonstrate that
VRP pretreatment is capable of providing protection against
lethal challenge with a heterologous virus. However, the mech-
anism of this protection may involve specific elements or com-
partments of the host response to which not all viruses are
universally sensitive to the same extent.
DISCUSSION
Countless studies have documented the specific changes in-
duced as an invading pathogen is sensed and the host response
is mounted during viral infection. However, few studies de-
scribe, on a molecular level, how the entire infected animal is
affected systemically, particularly in tissues that are distal to
the site(s) of active viral replication. Using VRP, we examined
the host response at the initial site of active viral replication in
vivo, while simultaneously monitoring the downstream re-
sponse in distal uninfected tissues within the same animal,
without the complication of viral spread. A unique, whole-
animal profile of the host response to primary infection re-
sulted, including the induction of several IFN-stimulated
genes, namely those coding for Isgf3, IP-10, p56, and IFN-,
all with well-documented roles in innate immunity (30, 45, 47,
62, 67, 70, 71). This rapid, systemic induction of a diverse range
of antiviral genes suggests that the invading pathogen was
sensed and an innate immune response initiated on an animal-
wide scale almost immediately.
This innate antiviral state induced by peripheral infection
with VRP rapidly promoted a protective response, as short-
duration VRP pretreatment protected animals from death fol-
lowing virulent VEE challenge. Future studies will explore
whether any individual gene product is solely responsible for
the observed protective innate response or whether a particu-
lar panel of antiviral activity is crucial for VRP-induced immu-
nity. While the exact mechanisms underlying the protection
mediated by VRP pretreatment remain to be fully defined, our
study outlines several critical parameters.
There is a temporal correlation between the capacity of
VRP pretreatment to bestow protection and the systemic in-
nate response induced in pretreated animals. Mice challenged
with VEE at times during which strong antiviral and IFN
responses were demonstrated (e.g., at 6, 12, and 24 h post-VRP
pretreatment) were completely protected from death. In con-
trast, when animals were challenged with VEE at times during
which the antiviral gene response and serum IFN levels were
relatively low (e.g., at 1 h and 3 h post-VRP pretreatment),
they were not protected from death (100% and 50% mortality
rates, respectively [data not shown]). Taken together, these
results suggest that the rapidly induced innate response ob-
served in VRP-pretreated animals may largely contribute to
protection.
Indeed the most obvious candidate responsible for inducing
this systemic response may be IFN itself, particularly given the
rapidity with which the protective state is established. Numer-
ous studies have described the sensitivity of VEE to the host
IFN response (2, 10, 25, 34, 37, 64), including the dramatic
acceleration of VEE-induced mortality in mice deficient for
IFN-/R with VEE (28, 57, 61, 73). Here, we observed a
complete loss of the early antiviral gene response following
VRP pretreatment observed in the brain of mice deficient for
the IFN-/R, further implicating the IFN response as a key
mediator of the initial response to VRP infection.
However, IFN alone may not solely be responsible. While
IFN is necessary for protection against lethal VEE infection,
past studies have demonstrated that the administration of IFN
or IFN-inducing agents—e.g., double-stranded RNA, poly
(I-C), or lipopolysaccharide—prior to VEE challenge is not
sufficient to protect animals from death (8, 28, 42, 48). Fur-
thermore, a recent study comparing the innate host responses
to VRP infection in control and IFN-/R/ dendritic cells
suggested that IFN-mediated signaling may not be the primary
paracrine mediator of the innate response in bystander cells
(39). Future studies designed to transfer serum from VRP-
pretreated mice to naïve animals (including IFN-/R/
mice) prior to VEE challenge should define the soluble serum
components critical to the observed protection.
While VRP pretreatment was not sufficient to protect ani-
mals from death upon intracranial challenge with VEE, it did
extend the average survival time of these animals. Interest-
ingly, the shortest VRP pretreatment duration (6 h) led to the
most significant extension in survival time. This phenomenon
may reflect a relatively tight temporal window following intra-
cranial challenge with VEE during which the antiviral response
can be effective in limiting or delaying peak VEE growth within
this specific tissue compartment. Accordingly, a direct relation-
ship may exist between challenge virus replication kinetics and
the protective capability of VRP pretreatment.
The substantial reduction in challenge virus titers in the
serum and brain of pretreated animals suggests that viral in-
vasion of the brain following peripheral challenge was success-
fully blocked or largely limited as a result of the VRP pretreat-
ment. In previous studies, a critical threshold of at least 104
PFU/ml of VEE in the serum was required for VEE to effec-
tively seed infection of the neuroepithelium and invade the
central nervous system (K. A. Bernard and R. E. Johnston,
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unpublished data). Therefore, it remains unclear whether the
reduction in challenge virus titers in the brains of VRP-pre-
treated animals was the result of a protective state induced in
the neuroepithelium that limited neuroinvasion, a conse-
quence of the overall reduction in serum viremia, or perhaps a
combination of both. Further experimentation exploring mor-
tality, antiviral gene responses, and challenge virus titers in
animals receiving a range of VRP pretreatment doses should
further elucidate the mechanism(s) by which the brain is pro-
tected within this system.
A potential trivial explanation for VRP-mediated protection
in this model is direct homologous interference between rep-
licon and challenge virus particles; however, such a mechanism
is not supported by our studies. The VRP pretreatments and
subsequent VEE challenge were either administered in oppos-
ing footpads or separated completely between the footpad and
nasal cavity, thereby functionally isolating the path of initial
replication. Elements of the adaptive immune response are
also unlikely to play a major role in our protection model, as
the time required to mount a protective antibody response
strongly argues against involvement of VEE-specific antibody.
In fact, detectable levels of VEE-specific serum immunoglob-
ulin G are not evident until 5 days postinoculation, even at high
viral doses (5). Nonetheless, we are currently investigating the
contribution, if any, of the early adaptive response utilizing
mice deficient in B and T cells.
Our results demonstrate that VRP pretreatment is capable
of providing protection against both homologous VEE chal-
lenge and heterologous challenge with influenza virus. How-
ever, the same pretreatment regimen was incapable of protect-
ing mice from a virulent challenge with VSV. The differential
capability of VRP pretreatment to protect against heterolo-
gous viral challenge may largely be due to the magnitude or
kinetics of the antiviral response. The course of VSV patho-
genesis in vivo is generally extended in comparison to that of
VEE. Therefore, the rapidly established VRP antiviral re-
sponse may have already begun to resolve at times critical to
suppressing VSV replication. In contrast, VEE and influenza
virus tend to replicate and disseminate quickly in vivo. For
example, peak serum viremia is established by 12 to 24 h
following peripheral VEE inoculation. Therefore, administer-
ing the VRP pretreatment at 6, 12, or 24 h prior to challenge
in effect allows the antiviral response to reach the peak state at
the time of VEE inoculation and/or during the period most
critical to inhibiting VEE replication and spread.
It is also plausible that VEE, influenza virus, and VSV are
differentially sensitive to the particular antiviral response pro-
file induced by VRP pretreatment. The action of IFN-induced
genes can be quite virus specific, and a particular gene product
or combination of responses may be required for complete
protection (38, 59, 62). Alternatively, VRP-pretreated animals
may lapse into a temporary state of IFN unresponsiveness
during a critical point in VSV replication, a phenomenon that
has been described to enhance susceptibility to secondary in-
fection through transient immunosuppression (1). Future stud-
ies exploring different parameters of pretreatment and chal-
lenge models will aid in further defining the specific antiviral
parameters that are most effective against alphavirus infection
as well as other heterologous challenge viruses.
The rapid and robust, yet transient, activation of a systemic
antiviral response in animals receiving VRP pretreatment
sheds new light on the dynamics of virus replication and the
host response. Within just a few short hours following infection
of the first cells, the animal begins to respond and is instantly
changed. The initial infection leads to the induction of immune
modulators that act in an autocrine fashion to amplify this
response. Paracrine mediators then act to rapidly induce a
response in surrounding bystander cells, leading to the produc-
tion of soluble mediators that act at a distance to alter tran-
scription in remote uninfected tissues. By just 6 h postinfec-
tion, and under conditions in which the infection is limited to
the first round of infected cells, the innate response is activated
throughout the body. These results suggest a new paradigm for
acute viral disease in which the ultimate pathogenesis of the
virus is largely determined by events in the first few moments
after infection. This response is capable of alerting the entire
infected animal to the presence of the invading pathogen and
largely determines the outcome of infection. In addition, con-
sidering that several alphavirus family members are in devel-
opment as vaccine vectors (9, 16, 43, 50, 52, 54), insights gained
from this model may influence the design of future preventa-
tive or therapeutic vaccines.
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